Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 2716 AL 2730

Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial

Nasrallah IM, Gaussoin SA, Pomponio R, Dolui S, Erus G, Wright CB, Launer LJ, Detre JA, Wolk DA, Davatzikos C, Williamson JD, Pajewski NM, Bryan RN; SPRINT Research Group.

JAMA Neurol. 2021 May 1;78(5):568-577. doi: 10.1001/jamaneurol.2021.0178.

Therapy for Alzheimer's disease: Missing targets and functional markers?

Stoiljkovic M, Horvath TL, Hajós M.

Ageing Res Rev. 2021 Jul;68:101318. doi: 10.1016/j.arr.2021.101318. Epub 2021 Mar 9.

Fluid Biomarkers in Clinical Trials for Alzheimer's Disease: Current and Future Application

Yang J, Jia L, Li Y, Qiu Q, Quan M, Jia J.

J Alzheimers Dis. 2021;81(1):19-32. doi: 10.3233/JAD-201068.

Recent Advances in Imaging of Preclinical, Sporadic, and Autosomal Dominant Alzheimer's Disease

Buckley RF.

Neurotherapeutics. 2021 Apr;18(2):709-727. doi: 10.1007/s13311-021-01026-5. Epub 2021 Mar 29.

The PKR/P38/RIPK1 Signaling Pathway as a Therapeutic Target in Alzheimer's Disease

Hugon J, Paquet C.

Int J Mol Sci. 2021 Mar 19;22(6):3136. doi: 10.3390/ijms22063136.

Monoclonal antibody therapy efficacy can be boosted by combinations with other treatments: Predictions using an integrated Alzheimer's Disease Platform

Karelina T, Lerner S, Stepanov A, Meerson M, Demin O.

CPT Pharmacometrics Syst Pharmacol. 2021 Jun;10(6):543-550. doi: 10.1002/psp4.12628. Epub 2021 May 2.

Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges

Cano A, Turowski P, Ettcheto M, Duskey JT, Tosi G, Sánchez-López E, García ML, Camins A, Souto EB, Ruiz A, Marquié M, Boada M.

J Nanobiotechnology. 2021 Apr 29;19(1):122. doi: 10.1186/s12951-021-00864-x.

A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity analysis

West T, Kirmess KM, Meyer MR, Holubasch MS, Knapik SS, Hu Y, Contois JH, Jackson EN, Harpstrite SE, Bateman RJ, Holtzman DM, Verghese PB, Fogelman I, Braunstein JB, Yarasheski KE.

Mol Neurodegener. 2021 May 1;16(1):30. doi: 10.1186/s13024-021-00451-6.

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH.

Lancet Neurol. 2021 Jun;20(6):484-496. doi: 10.1016/S1474-4422(21)00066-1. Epub 2021 Apr 29.

Insulin Resistance as a Common Link Between Current Alzheimer's Disease Hypotheses

Alves SS, Silva-Junior RMPD, Servilha-Menezes G, Homolak J, Šalković-Petrišić M, Garcia-Cairasco N.

J Alzheimers Dis. 2021;82(1):71-105. doi: 10.3233/JAD-210234.

The clinical correlation of proinflammatory and anti-inflammatory biomarkers with Alzheimer disease: a meta-analysis

Anuradha U, Kumar A, Singh RK.

Neurol Sci. 2022 Jan;43(1):285-298. doi: 10.1007/s10072-021-05343-7. Epub 2021 May 25.

Alzheimer's disease research progress in Australia: The Alzheimer's Association International Conference Satellite Symposium in Sydney

Sexton CE, Anstey KJ, Baldacci F, Barnum CJ, Barron AM, Blennow K, Brodaty H, Burnham S, Elahi FM, Götz J, Jeon YH, Koronyo-Hamaoui M, Landau SM, Lautenschlager NT, Laws SM, Lipnicki DM, Lu H, Masters CL, Moyle W, Nakamura A, Pasinetti GM, Rao N, Rowe C, Sachdev PS, Schofield PR, Sigurdsson EM, Smith K, Srikanth V, Szoeke C, Tansey MG, Whitmer R, Wilcock D, Wong TY, Bain LJ, Carrillo MC.

Alzheimers Dement. 2022 Jan;18(1):178-190. doi: 10.1002/alz.12380. Epub 2021 May 31.

Alzheimer's Disease Animal Models: Elucidation of Biomarkers and Therapeutic Approaches for Cognitive Impairment

Nakai T, Yamada K, Mizoguchi H.

Int J Mol Sci. 2021 May 24;22(11):5549. doi: 10.3390/ijms22115549.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias